Protective effect of edaravone on adriamycin-induced cardiotoxicity in rats

Aim: Adriamycin (ADR) is an antineoplastic drug that is widely used in chemotherapy but its cardiotoxicity is the most important side effect that limits the clinical use of this drug. In this study, we investigated of edaravone (EDO), which is a potent antioxidant, ADR-induced cardiotoxicity model in rats by electrocardiographic (ECG), biochemical and scintigraphic methods. Methods: Twenty-eight adult male Wistar-Albino rats were randomly separated into four groups; namely control (CON); Adriamycin (ADR); substance control of edaravone (EDO), edaravone + adriamycin (EDO+ADR) groups. Cardiotoxicity in rats was induced by adriamycin injection (cumulative dose:18 mg/kg, intraperitoneal-i.p.-) at an interval of 24 hours (h) on the 5th, 6th and 7th days. Rats receiving edaravone treatment in the adriamycin group administration edaravone (30 mg/kg/day, i.p.) for 7 days and were injected with adriamycin (18 mg/kg, i.p.) on 5th, 6th and 7th days. On the 8th day electrocardiography (ECG), biochemical and technetium-99m pyrophosphate (99mTc-PYP) scintigraphic parameters were assessed. Results: ADR induction caused changes in the ECG pattern, decreased heartbeat, P wave and QRS complex duration, increased both ST-segment amplitude and QT interval duration (p < 0,001), increase in the biochemical markers [blood urea nitrogen (BUN), creatine kinase (CK), cardiac troponin T (cTnT)], and elevated 99mTc-PYP uptake level (p < 0,001). EDO treatment prevented all the parameters of ADR-induced cardiotoxicity in rats, by significantly decreased all ADR-associated conduction abnormalities in ECG (p < 0.001), decreased 99mTc-PYP uptake (p < 0.001) and serum BUN, CK and cTnT, (p < 0.001). Conclusions: Our data demonstrate that EDO has cardioprotective effects on DOX-induced cardiotoxicity. At the same time, this study suggested that 99mTc-PYP may be using as a non-invasive method for the early diagnosis of ADR-induced cardiotoxicity